Funding Infusion Won't Cure Bluebird Of Its Problems
The company is hoping its gene therapies can achieve lift-off in 2024, but analysts think weak demand and strong competition from Vertex could prove fatal for Bluebird.
The company is hoping its gene therapies can achieve lift-off in 2024, but analysts think weak demand and strong competition from Vertex could prove fatal for Bluebird.